ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tenofovir alafenamide

Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.

Drug pageTenofovir alafenamide: every studyMany companies study it; this page follows only the 61 they lead. All 140 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 23, 202361 company-led studies, 10 open or runningNext primary completion: Jun 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only499 open or runningphase 4since Oct 23, 2023May 13, 2002Jun 2027phase 4 · NCT06337032
Johnson & Johnson70 open or runningphase 3since Oct 17, 2014Oct 17, 2014none ahead
Henan Genuine Biotechits history only10 open or runningphase 1since May 13, 2025May 13, 2025none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Sep 9, 2024Sep 9, 2024none ahead
New Discoveryits history only10 open or runningphase 4since Dec 6, 2019Dec 6, 2019none ahead
The Crofoot Research Centerits history only10 open or runningphase 4since May 12, 2020May 12, 2020none ahead
Xiamen Amoytop Biotechits history only11 open or runningno phasesince Nov 24, 2024Nov 24, 2024May 31, 2029NCT06707922

Also a collaborator on its studies: Merck and F-star Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2014First study: phase 3 study in Acquired Immunodeficiency SyndromeFirst studyNCT02269917 · 1,149 enrolled · United States, Belgium, Canada and more
  2. Apr 27, 2015Phase 3 study in Acquired Immunodeficiency SyndromeNCT02431247 · 725 enrolled · United States, Belgium, Canada and more
  3. Jun 15, 2015Phase 1 study in Acquired Immunodeficiency SyndromeNCT02475135 · 72 enrolled · Belgium
  4. Oct 15, 2015Phase 1 study in Acquired Immunodeficiency SyndromeNCT02578550 · 126 enrolled · Netherlands
  5. Dec 5, 2016Phase 1 study in HealthyNCT02984852 · 30 enrolled · United States
  6. Jan 21, 2020Phase 1 study in HealthyNCT04236453 · 16 enrolled · Netherlands
  7. Dec 3, 2020Phase 1 study in HealthyNCT04661397 · 37 enrolled · Netherlands

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule

Studies

All 7 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04661397Healthy · Netherlands1CompletedJul 2, 202137
NCT04236453Healthy · Netherlands1TerminatedApr 10, 202016
NCT02984852Healthy · United States1CompletedFeb 201730
NCT02578550Acquired Immunodeficiency Syndrome · Netherlands1CompletedFeb 2016126
NCT02475135Acquired Immunodeficiency Syndrome · Belgium1CompletedAug 14, 201572
NCT02431247Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more3CompletedMar 2, 2017725
NCT02269917Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more3CompletedFeb 20171,149

How it is read

Names in the registry

  • “E/C/F/TAF”, 17 entries
  • “TAF”, 12 entries
  • “B/F/TAF”, 10 entries
  • “F/TAF”, 8 entries
  • “B/F/TAF (TOS)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.